icon-folder.gif   Conference Reports for NATAP  
 
  EACS - 12th European AIDS Conference
November 11-14, 2009
Cologne, Germany
Back grey_arrow_rt.gif
 
 
 
Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-na´ve HIV-1 infected patients: ARTEN Study Week 48 results
 
 
  Reported by Jules Levin
EACS Nov 13 2009, Cologne, Germany
 
D Podzamczer1, V Soriano2, J Andrade-Villanueva3, B Clotet4, S Taylor5, J Rockstroh6, P Domingo7, P Reiss8, HJ Gellermann9, V Cairns9, L de Rossi9
 
1. Hospital Universitario de Bellvitge, Barcelona, Spain; 2. Hospital Carlos III, Madrid, Spain; 3. Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico; 4. Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation, Barcelona, Spain; 5. Birmingham Heartlands Hospital, Birmingham, UK; 6. University of Bonn, Bonn, Germany; 7. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 8. Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and 9. Boehringer Ingelheim, Ingelheim, Germany

image002.gif

image004.gif

Soriano et al. IAS 2009, Cape Town, South Africa, Poster LBPE07. Nevirapine is not indicated for qd dosing. The safety and efficacy of qd dosing have not been established

image006.gif

image008.gif

image010.gif

image012.gif

image014.gif

image016.gif

image018.gif

image020.gif

image022.gif

image024.gif

image026.gif